Clinical Trial Detail

NCT ID NCT02573220
Title Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Chicago

colorectal cancer


Cetuximab + Fluorouracil + Irinotecan + Leucovorin

Age Groups: adult

Additional content available in CKB BOOST